Trial Profile
An Open-Label, Partially Randomized Trial to Evaluate the Efficacy, Safety and Tolerability of a 4-month Treatment of Bedaquiline Plus Pretomanid Plus Moxifloxacin Plus Pyrazinamide (BPaMZ) Compared to a 6-month Treatment of HRZE/HR (Control) in Adult Participants With Drug-Sensitive Smear-Positive Pulmonary Tuberculosis (DS-TB) and a 6-month Treatment of BPaMZ in Adult Participants With Drug Resistant, Smear-Positive Pulmonary Tuberculosis (DR-TB)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 10 Nov 2023
Price :
$35
*
At a glance
- Drugs Bedaquiline (Primary) ; Moxifloxacin (Primary) ; Pretomanid (Primary) ; Pyrazinamide (Primary) ; Ethambutol; Isoniazid; Rifampicin
- Indications Tuberculosis
- Focus Therapeutic Use
- Acronyms SimpliciTB
- Sponsors Global Alliance for TB Drug Development
- 22 Feb 2023 Primary endpoint (Time to culture conversion to negative status over 8 weeks) has been met, as per results presented at the 30th Conference on Retroviruses and Opportunistic Infections 2023.
- 22 Feb 2023 Results assessing hepatic safety of pretomanid regimens with or without pyrazinamide in tuberculosis patients, presented at the 30th Conference on Retroviruses and Opportunistic Infections 2023.
- 23 Jun 2022 Status changed from active, no longer recruiting to completed.